Skip Navigation


Annals of Oncology Advance Access originally published online on July 12, 2009
Annals of Oncology 2009 20(12):2007-2012; doi:10.1093/annonc/mdp259
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/12/2007    most recent
mdp259v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Delgado, J.
Right arrow Articles by Sierra, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delgado, J.
Right arrow Articles by Sierra, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

hematologic malignancies

Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case–control retrospective analysis

J. Delgado1,*, S. Pillai2, N. Phillips2, S. Brunet1, G. Pratt2, J. Briones1, R. Lovell2, R. Martino1, J. Ewing2, A. Sureda1, D. W. Milligan2 and J. Sierra1

1 Department of Haematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
2 Department of Haematology, Heart of England National Health Service Trust, Birmingham, UK

* Correspondence to: Dr J. Delgado, Servei d'Hematologia Clinica, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, Barcelona 08025, Spain. Tel: +34-935565601; Fax: +34-935565659; E-mail: jdelgadog{at}santpau.cat

Background: Reduced-intensity conditioning (RIC) allogeneic haemopoietic cell transplantation (allo-HCT) is increasingly considered as a therapeutic option for younger patients with poor-risk chronic lymphocytic leukaemia (CLL). In this retrospective analysis, we assessed the outcomes of CLL patients undergoing RIC allo-HCT compared with a group of matched controls that were candidates for transplantation but did not have a suitable donor or refused the procedure.

Patients and methods: Cases comprised 37 patients who underwent RIC allo-HCT. Haemopoietic cell grafts were harvested from HLA-matched siblings (27) and unrelated donors (7). Controls consisted of 43 patients from the same institutions who received conventional therapy only. Matching variables were age at diagnosis and time to first CLL-specific therapy.

Results: Both patient groups were well balanced in terms of cytogenetics by FISH, CD38 and ZAP-70 expression, and immunoglobulin heavy-chain variable region mutational status. Median overall survival was 113 months for HCT patients and 85 months for controls when calculated from time of diagnosis (P = 0.072) and 103 and 67 months, respectively, when calculated from time of first therapy (P = 0.041).

Conclusion: RIC allo-HCT is a reasonable option for patients with high-risk CLL. However, these results require confirmation before the procedure can be recommended outside clinical trials.

Key words: allogeneic HCT, case control study, chronic lymphocytic leukaemia

Received for publication November 4, 2008. Revision received March 20, 2009. Accepted for publication March 30, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.